Recruiting

Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.

I'm interested View official listing

ClinicalTrials.gov IDNCT06067399

PhaseNot Applicable

Enrollment250

SponsorNew Valley University

Age40 Years and older

SexALL

I'm interested View official listing

Conditions studied

Type 2 Diabetes

About this study

Interventions

Diagnostic Test: Glycated hemoglobin (HbA1C) — Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
Diagnostic Test: RDW — Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
Diagnostic Test: Lipid profile — Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )

Primary outcomes

To assess the correlation between RDW and HbA1C levels in patients with T2DM before and after glycemic control. ("At time of inclusion in the study", "3 months", "6 months")

Eligibility information

Inclusion Criteria: * Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%) Exclusion Criteria: 1. Patients diagnosed to have type 1 diabetes. 2. Patients are diagnosed to have secondary diabetes. 3. Clinical states associated with increased RDW: * Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate. * After blood transfusions * Pregnancy, thrombotic thrombocytopenic purpura and inflammatory bowel disease.

Study locations

New Valley University- Faculty of Medicine, Al Khārjah, Egypt

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-13.